Holen Sie sich die Stockscreener-App
6.56
5.00%
-0.34
Schlusskurs vom Vortag:
$6.90
Offen:
$6.68
24-Stunden-Volumen:
1.53M
Relative Volume:
0.84
Marktkapitalisierung:
$444.61M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.4047
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
-13.64%
1M Leistung:
-60.32%
6M Leistung:
-73.74%
1J Leistung:
-82.70%
1-Tages-Spanne:
$6.24
$6.80
1-Wochen-Bereich:
$6.24
$7.43
52-Wochen-Spanne:
$6.24
$39.34
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.57 | 444.61M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.68 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.39 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
559.38 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.97 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
240.59 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener
Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks
Arvinas Presents First-in-Human Data for Investigational - GlobeNewswire
Game-Changing Parkinson's Drug Shows 90% Target Reduction in First Human Trial - Stock Titan
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Yahoo Finance
Edmond DE Rothschild Holding S.A. Takes Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat
BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat
Where are the Opportunities in (ARVN) - news.stocktradersdaily.com
Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India
Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire
Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat
Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat
Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat
Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas chief medical officer sells $74,372 in common stock - Investing.com India
Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com
Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas (NASDAQ:ARVN) Rating Lowered to Neutral at The Goldman Sachs Group - MarketBeat
Arvinas (NASDAQ:ARVN) Given New $32.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Bank of America Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 1-Year LowHere's What Happened - MarketBeat
Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):